期刊文献+

PLT、PIVKA-Ⅱ、ALB联合检测在AFP阴性肝细胞癌和肝硬化中的鉴别诊断价值

The value of combined detection of PLT,PIVKA-Ⅱand ALB in the differential diagnosis of AFP-negative hepatocellular carcinoma and cirrhosis
下载PDF
导出
摘要 目的探讨异常凝血酶原(PIVKA-Ⅱ)、血小板计数(PLT)、清蛋白(ALB)联合检测在甲胎蛋白阴性肝细胞癌(AFP-NHCC)和肝硬化(LC)中的鉴别诊断价值。方法选取2021年1月至2023年3月在广西医科大学第一附属医院住院治疗的69例AFP-NHCC患者作为AFP-NHCC组,另选取同期52例LC患者作为LC组,检测两组PLT、PIVKA-Ⅱ、ALB水平,并绘制受试者工作特征(ROC)曲线分析3项指标在AFP-NHCC和LC中的鉴别诊断价值。结果AFP-NHCC组PLT、PIVKA-Ⅱ、ALB水平均明显高于LC组,差异均有统计学意义(P<0.05)。ROC曲线分析结果显示,PLT、PIVKA-Ⅱ、ALB单独检测鉴别诊断AFP-NHCC和LC的曲线下面积(AUC)分别为0.758、0.879、0.941,3项指标联合检测鉴别诊断AFP-NHCC和LC的灵敏度为91.3%,特异度为94.2%,AUC为0.977。结论PLT、PIVKA-Ⅱ、ALB联合检测可以弥补单独检测的劣势,可提高对AFP-NHCC与LC之间的鉴别诊断价值,具有重要的临床应用价值。 Objective To investigate the value of combined detection of abnormal prothrombin induced by abnormal prothrombin(PIVKA-Ⅱ),platelet count(PLT)and albumin(ALB)in the differential diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma(AFP-NHCC)and liver cirrhosis(LC).Methods A total of 69 AFP-NHCC patients hospitalized in the First Affiliated Hospital of Guangxi Medical University from January 2021 to March 2023 were selected as the AFP-NHCC group,and 52 LC patients during the same period were selected as the LC group.The levels of PLT,PIVKA-Ⅱand ALB in the two groups were detected.Receiver operating characteristic(ROC)curve was drawn to analyze the differential diagnostic value of three parameters in AFP-NHCC and LC.Results The levels of PLT,PIVKA-Ⅱand ALB in AFP-NHCC group were significantly higher than those in LC group,and the differences were statistically significant(P<0.05).ROC curve analysis showed that the area under the curve(AUC)of PLT,PIVKA-Ⅱand ALB in the differential diagnosis of AFP-NHCC and LC were 0.758,0.879 and 0.941 respectively.The sensitivity of combined detection of three indicators in the differential diagnosis of AFP-NHCC and LC was 91.3%,the specificity was 94.2%,and the AUC was 0.977.Conclusion Combined detection of PLT,PIVKA-Ⅱand ALB can make up for the disadvantages of individual detection and improve the differential diagnosis value between AFP-NHCC and LC,which has important clinical application value.
作者 韦芳沂 阮学莲 蒙继煜 陈华平 秦雪 WEI Fangyi;RUAN Xuelian;MENG Jiyu;CHEN Huaping;QIN Xue(Department of Clinical Laboratory,the First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi 530021,China;Guangxi University Key Laboratory of Clinical Laboratory Diagnostics,Nanning,Guangxi 530021,China)
出处 《检验医学与临床》 CAS 2024年第15期2155-2158,共4页 Laboratory Medicine and Clinic
基金 国家自然科学基金资助项目(81960390)。
关键词 甲胎蛋白阴性肝细胞癌 肝硬化 异常凝血酶原 血小板计数 清蛋白 alpha-fetoprotein-negative hepatocellular carcinoma liver cirrhosis abnormal prothrombin blood platelet count albumin
  • 相关文献

参考文献2

二级参考文献37

  • 1[1]Bosch FX,Ribes J,Diaz M,Cleries R.Primary liver cancer:worldwide incidence and trends.Gastroenterology 2004; 127:S5-16
  • 2[2]Bosch FX,Ribes J,Borras J.Epidemiology of primary liver cancer.Semin Liver Dis 1999; 19:271-285
  • 3[3]Zaman SN,Melia WM,Johnson RD,Portmann BC,Johnson PJ,Williams R.Risk factors in development of hepatocellular carcinoma in cirrhosis:prospective study of 613 patients.Lancet 1985; 1:1357-1360
  • 4[4]Benvegnu L,Gios M,Boccato S,Alberti A.Natural history of compensated viral cirrhosis:a prospective study on the incidence and hierarchy of major complications.Gut 2004; 53:744-749
  • 5[5]Liaw YF,Tai DI,Chu CM,Lin DY,Sheen IS,Chen TJ,Pao CC.Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis.A prospective study.Gastroenterology 1986; 90:263-267
  • 6[6]Zhang BH,Yang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol 2004; 130:417-421
  • 7[7]E1-Serag HB,Mason AC,Key C.Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996in the United States.Hepatology 2001; 33:62-65
  • 8[8]Bruix J,Sherman M,Llovet JM,Beaugrand M,Lencioni R,Burroughs AK,Christensen E,Pagliaro L,Colombo M,Rodes J.EASL panel of rxperts on HCC.Clinical management of hepatocellular carcinoma.Conclusions of the barcelona-2000EASL conference.European sssociation for the dtudy of the liver.J Hepatol 2001; 35:421-430
  • 9[9]Liebman HA,Furie BC,Tong MJ,Blanchard RA,Lo KJ,Lee SD,Coleman MS,Furie B.Des-gamma-carboxy (abnormal)prothrombin as a serum marker of primary hepatocellular carcinoma.N Engl J Med 1984; 310:1427-1431
  • 10[10]Soulier JP,Gozin D,Lefrere JJ.A new method to assay desgamma-carboxyprothrombin.Results obtained in 75 cases of hepatocellular carcinoma.Gastroenterology 1986; 91:1258-1262

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部